Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

New study explores parent satisfaction with research study on treating severe childhood aggression

A new study of families participating in a clinical trial to treat children with severe physical aggression explored the factors affecting parent satisfaction with the research study.

21 Apr 2015

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders.

7 Apr 2015

Death risk is higher for dementia patients who take antipsychotic drugs, new study shows

Drugs aimed at quelling the behavior problems of dementia patients may also hasten their deaths more than previously realized, a new study finds.

19 Mar 2015

People with severe schizophrenia have major differences in brain networks

People with a severe form of schizophrenia have major differences in their brain networks compared to others with schizophrenia, bipolar disorder and healthy individuals, a new study from the Centre for Addiction and Mental Health shows.

19 Mar 2015

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal.

5 Mar 2015

Non-drug approaches work better in people with Alzheimer's disease, dementia

Doctors write millions of prescriptions a year for drugs to calm the behavior of people with Alzheimer's disease and other types of dementia. But non-drug approaches actually work better, and carry far fewer risks, experts conclude in a new report.

4 Mar 2015

Study: 31 states implement new policies for 'atypical' prescribing of antipsychotics to children

With a concern about inappropriate prescribing of antipsychotic medications to children, 31 states have implemented prior authorization policies for atypical antipsychotic prescribing, mostly within the past 5 years, and with most states applying their policies to children younger than 7 years of age, according to a study in the March 3 issue of JAMA.

4 Mar 2015

Study explores use of antipsychotic medications among pediatric patients

More kids nationwide are taking medications designed to treat such mental illnesses as schizophrenia and bipolar disorder, and pediatricians and psychiatrists at the University of Vermont want to know why.

2 Mar 2015

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus.

20 Feb 2015

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report.

19 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Endogenous cannabinoids linked to weight gain in people with schizophrenia

Cannabinoids may be involved in the weight gain that occurs in people with schizophrenia who are treated with the antipsychotic olanzapine, according to a pilot study published in the Journal of Clinical Psychopharmacology by researchers at the Institut universitaire en santé mentale de Montréal and Université de Montréal.

5 Feb 2015

Researchers identify a common pattern across different psychiatric disorders

In a study analyzing whole-brain images from nearly 16,000 people, researchers at the Stanford University School of Medicine identified a common pattern across a spectrum of psychiatric disorders that are widely perceived to be quite distinct.

4 Feb 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss.

16 Jan 2015

Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make your skin more sensitive to the sun and this summer season NPS MedicineWise advises Australians to check their medicines packaging for warnings to avoid excessive skin exposure to sunlight and sunlamps.

9 Jan 2015

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015